4-1BBL AND IL-12 COMBINATION THERAPY FOR GLIOBLASTOMA
Summary
The USPTO published patent application US20260097096A1, a new intellectual property grant covering methods of treating glioblastoma using 4-1BBL administered via adeno-associated virus (AAV-F) in combination with recombinant IL-12 delivered by intratumoral injection. The patent names Koen Breyne, Xandra O. Breakefield, and Thorsten R. Mempel as inventors. Biotech and pharmaceutical companies developing cancer immunotherapies must monitor this IP landscape.
What changed
The USPTO published patent application US20260097096A1, a new intellectual property grant covering methods of treating glioblastoma using 4-1BBL in combination with recombinant IL-12. The therapy involves administering 4-1BBL via adeno-associated virus vectors (AAV-F) and delivering IL-12 through intratumoral injection.
This patent grant affects biotechnology and pharmaceutical companies developing cancer immunotherapies, particularly those working on glioblastoma treatments, immune checkpoint agonists, or AAV-based gene therapies. Companies should conduct freedom-to-operate analyses, monitor patent expiration timelines, and evaluate potential licensing or partnership opportunities. The patent claims priority to September 27, 2023.
What to do next
- Monitor patent landscape for freedom-to-operate implications
- Assess licensing opportunities for glioblastoma combination therapies
- Evaluate impact on oncology pipeline development strategies
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
4-1BBL AND IL-12 THERAPY FOR TREATMENT OF GLIOBLASTOMA
Application US20260097096A1 Kind: A1 Apr 09, 2026
Inventors
Koen Breyne, Xandra O. Breakefield, Thorsten R. Mempel
Abstract
Provided herein are methods of treating glioblastoma including administering to a subject having glioblastoma a therapeutically effective amount of a pharmaceutical composition comprising 4-1BBL, optionally in combination with recombinant IL-12. The 4-1BBL can be provided to the subject via an adeno-associated virus, for example AAV-F, and the IL-12 can be provided by intratumoral injection.
CPC Classifications
A61K 38/177 A61K 38/208 A61K 48/005 A61P 35/00 C12N 15/86 C12N 2740/15043 C12N 2750/14143
Filing Date
2023-09-27
Application No.
19115409
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.